This project has been flagged by a community member as inappropriate due to reason below.*

Survey

Slingshot members are conducting a survey! The topic is:

Quarterly Survey_Narcolepsy and Avadel’s Lumryz April 2023

Ticker(s): AVDL, JAZZ

Who's being surveyed?

The survey includes 20 physicians (Neurologist/Psychiatrist) treating Narcolepsy.

Survey Questions
Q1.

How many patients with Narcolepsy are under your care?

Q2.

Are you familiar with Once Nightly Sodium Oxybate (Trade name: Lumryz)?

Q3.

How many pts are currently on Xyrem?

Q4.

How many pts on Xyrem have not switched to Xywav? 

Q5.

Why is that?

Q6.

How many of your pts on Xyrem would you consider switching to Lumryz's once-nightly dosing regimen?

Q7.

How many pts are currently on Xywav? 

Q8.

How many of your pts on Xywav would you consider switching to Lumryz's once-nightly dosing regimen?

Q9.

Do you believe that Lumryz's once-nightly treatment will grow the oxybate market?

Q10.

What percent will Lumry grow the oxybate market?

Q11.

In the clinical studies of Lumryz, weight loss was observed in some patients. Do you think this weight loss will be seen in clinical practice? Why or why not? Please be specific.

Q12.

What percentage of your narcolepsy patients do you believe would benefit from Lumryz's weight loss benefits?

Q13.

What do you believe would be the main reason a patient would choose to take Lumryz instead of the prior options for treating narcolepsy?

Q14.

What other benefits does Lumryz offer beyond its once-nightly dosing regimen?

Q15.

On a scale 1-10 (where 1 is low and 10 is high) how excited are you about the potential benefits of Lumryz for your patients with narcolepsy?

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.